DOES USE OF INHALED FLUTICASONE PRIOR TO AN ADENOSINE 5'MONOPHOSPHATE (AMP) BRONCHIAL PROVOCATION TEST AFFECT THE PERCEPTION OF DYSPNOEA?

Phase 3

Completed

• Conditions: Inflammatory and Immune System - Allergies; Asthma; Allergic Rhinitis; Respiratory - Asthma

• Registration Number: ACTRN12605000611628
• Lead Sponsor: Woolcock Institute of Medical Research

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2005-10-06
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

Allergy to inhaled allergens. Mild asthma and rhinitis.

Exclusion Criteria

No exclusion criteria

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To investigate the acute effect of single dose of 250µg fluticasone propionate (FP) on perception of dyspnoea during AMP Bronchial provocative test, given 2 or 14hours pre test.[]

Secondary Outcome Measures

Name	Time	Method
Effect of acutely inhaled FP on FEV1, EF25-75%, IC and FVC.[All secondary outcomes are measured during and immediatly after the challenge.];Effect of AMP Bronchial Provocative test in development of nasal symptoms.[All secondary outcomes are measured during and immediatly after the challenge.];Effect of acutely inhaled FP on the nasal symptoms.[All secondary outcomes are measured during and immediatly after the challenge.]